Axa S.A. Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Axa S.A.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$83.14 - $145.99 $4.63 Million - $8.13 Million	-55,656 Closed	0 $0
Q1 2022 Feb 14, 2023	BUY	$110.08 - $142.92 $6.13 Million - $7.95 Million	55,656 New	55,656 $6.6 Million
Q1 2022 May 13, 2022	SELL	$110.08 - $142.92 $593,441 - $770,481	-5,391 Reduced 8.83%	55,656 $6.6 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $863,262 - $1.29 Million	8,656 Added 16.52%	61,047 $8.41 Million
Q3 2021 Nov 15, 2021	BUY	$98.85 - $138.91 $1.03 Million - $1.45 Million	10,460 Added 24.95%	52,391 $7.28 Million
Q2 2021 Aug 13, 2021	SELL	$65.78 - $105.02 $209,509 - $334,488	-3,185 Reduced 7.06%	41,931 $4.07 Million
Q1 2021 May 14, 2021	BUY	$64.07 - $91.75 $52,601 - $75,326	821 Added 1.85%	45,116 $3.08 Million
Q4 2020 Feb 12, 2021	SELL	$65.07 - $98.24 $1.55 Million - $2.34 Million	-23,809 Reduced 34.96%	44,295 $3.8 Million
Q3 2020 Nov 13, 2020	SELL	$59.04 - $77.95 $38,789 - $51,213	-657 Reduced 0.96%	68,104 $4.43 Million
Q2 2020 Aug 14, 2020	BUY	$29.01 - $74.23 $120,333 - $307,906	4,148 Added 6.42%	68,761 $5.03 Million
Q1 2020 May 15, 2020	BUY	$27.51 - $57.29 $1.78 Million - $3.7 Million	64,613 New	64,613 $2.2 Million
Q1 2018 May 14, 2018	SELL	$22.49 - $34.56 $2.93 Million - $4.51 Million	-130,484 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$20.44 - $35.56 $2.67 Million - $4.64 Million	130,484	130,484 $3.52 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.